Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus adjuvanted vaccine - GSK/Xiamen Innovax Biotech

Next Previous
Drug Profile

Human papillomavirus adjuvanted vaccine - GSK/Xiamen Innovax Biotech

Alternative Names: Adjuvanted HPV-9 vaccine; HPV adjuvanted vaccine; Human Papillomavirus 9-valent vaccine

Latest Information Update: 29 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Xiamen Innovax Biotech
  • Developer GSK
  • Class Papillomavirus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Human papillomavirus infections

Most Recent Events

  • 14 Jun 2024 GlaxoSmithKline completes a phase I/II trial in Human papillomavirus infections (In adolescents, Prevention, In adults) in the US, Bulgaria, Czech Republic, Estonia, France, Germany, Lithuania, Poland (IM) (NCT05496231) (EudraCT2022-000090-15)
  • 22 Aug 2022 Phase-I/II clinical trials in Human papillomavirus infections (In adolescents, Prevention, In adults) in Bulgaria, Czech Republic, Estonia, France, Germany, Lithuania, Poland (IM) (NCT05496231) (EudraCT2022-000090-15)
  • 22 Aug 2022 Phase-I/II clinical trials in Human papillomavirus infections (Prevention, In adolescents, In adults) in USA (IM)(NCT05496231)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top